Drug Profile
Recombinant influenza virus vaccine - HK inno.N
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 23 Dec 2015 Phase-III clinical trials in Influenza virus infections in South Korea (unspecified route) (CJ Healthcare pipeline, December 2015)